Trial · NCT03496207
Results by group73
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 73
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Base Study: Change From Baseline in Pulmonary Vascular Resistance (PVR) at 24 Weeks | Placebo | Base Study: Change from Baseline in PVR at 24 Weeks | -27.6 | Standard Deviation 251.08 | dynes*sec/cm^5 |
| Base Study: Change From Baseline in Pulmonary Vascular Resistance (PVR) at 24 Weeks | Sotatercept 0.3 mg/kg | Base Study: Change from Baseline in PVR at 24 Weeks | -168.4 | Standard Deviation 262.93 | dynes*sec/cm^5 |
| Base Study: Change From Baseline in Pulmonary Vascular Resistance (PVR) at 24 Weeks | Sotatercept 0.7 mg/kg | Base Study: Change from Baseline in PVR at 24 Weeks | -258.9 | Standard Deviation 169.42 | dynes*sec/cm^5 |
| Base Study: Change From Baseline in Pulmonary Vascular Resistance (PVR) at 24 Weeks | Placebo | Baseline | 802.0 | Standard Deviation 331.05 | dynes*sec/cm^5 |
| Base Study: Change From Baseline in Pulmonary Vascular Resistance (PVR) at 24 Weeks | Sotatercept 0.3 mg/kg | Baseline | 772.0 | Standard Deviation 285.62 | dynes*sec/cm^5 |
| Base Study: Change From Baseline in Pulmonary Vascular Resistance (PVR) at 24 Weeks | Sotatercept 0.7 mg/kg | Baseline | 715.5 | Standard Deviation 267.11 | dynes*sec/cm^5 |
| Extension Period: Change From Baseline in PVR (Delayed-Start Analysis) | Placebo-Crossed Treatment Group | Extension Period: Change from Baseline in PVR (Delayed-Start Analysis) | -246.9 | Standard Deviation 300.01 | dynes*sec/cm^5 |
| Extension Period: Change From Baseline in PVR (Delayed-Start Analysis) | Continued Sotatercept Treatment Group | Extension Period: Change from Baseline in PVR (Delayed-Start Analysis) | -212.6 | Standard Deviation 254.24 | dynes*sec/cm^5 |
| Extension Period: Change From Baseline in PVR (Delayed-Start Analysis) | Placebo-Crossed Treatment Group | Baseline | 802.0 | Standard Deviation 331.05 | dynes*sec/cm^5 |
| Extension Period: Change From Baseline in PVR (Delayed-Start Analysis) | Continued Sotatercept Treatment Group | Baseline | 783.7 | Standard Deviation 371.59 | dynes*sec/cm^5 |
| Extension Period: Change From Baseline in PVR (Placebo-Crossed Analysis) | Placebo-Crossed Treatment Group | Extension Period: Change from Baseline in PVR (Placebo-Crossed Analysis) | -246.9 | Standard Deviation 300.01 | dynes*sec/cm^5 |
| Extension Period: Change From Baseline in PVR (Placebo-Crossed Analysis) | Placebo-Crossed Treatment Group | Baseline | 802.0 | Standard Deviation 331.05 | dynes*sec/cm^5 |
| Extension Period: Number of Participants Who Experienced One or More Adverse Events (AEs) | Extension Period: Placebo→Sotatercept 0.3 mg/kg | 14 | Participants | ||
| Extension Period: Number of Participants Who Experienced One or More Adverse Events (AEs) | Extension Period: Placebo→Sotatercept 0.7 mg/kg | 15 | Participants | ||
| Extension Period: Number of Participants Who Experienced One or More Adverse Events (AEs) | Extension Period: Sotatercept 0.3 mg/kg | 31 | Participants | ||
| Extension Period: Number of Participants Who Experienced One or More Adverse Events (AEs) | Extension Period: Sotatercept 0.7 mg/kg | 36 | Participants | ||
| Extension Period: Number of Participants Who Discontinued Study Treatment Due to an AE | Extension Period: Placebo→Sotatercept 0.3 mg/kg | 1 | Participants | ||
| Extension Period: Number of Participants Who Discontinued Study Treatment Due to an AE | Extension Period: Placebo→Sotatercept 0.7 mg/kg | 0 | Participants | ||
| Extension Period: Number of Participants Who Discontinued Study Treatment Due to an AE | Extension Period: Sotatercept 0.3 mg/kg | 1 | Participants | ||
| Extension Period: Number of Participants Who Discontinued Study Treatment Due to an AE | Extension Period: Sotatercept 0.7 mg/kg | 3 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03496207/results